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Reversal of radiation-induced cisplatin resistance in murine fibrosarcoma
cells by selective modulation of the cyclic GMP-dependent transduction
pathway
H Eichholtz-Wirth
GSF-Institutfuir Strahlenbiologie, D-85758 Neuherberg and Strahlenbiologisches Institut der Universitdt, Schillerstrasse 42,
D-80336 Munich, Germany.
Summary Cisplatin resistance, induced in murine fibrosarcoma cells (SSK) in vitro or in vivo by low-dose
irradiation, can be overcome by activation of the cyclic GMP(cGMP)-dependent transduction pathway. This is
mediated either by stimulating cGMP formation with sodium nitroprusside or by replacing cGMP with a
selective activator of the cGMP-dependent protein kinase, 8-bromo-cGMP. The cyclic AMP-dependent
transduction pathway is not involved in cisplatin resistance. Instead, activation of cAMP sensitises both
parental and resistant SSK cells equally to the action of cisplatin. There is a 1.8 to 2.5-fold increase in drug
toxicity, depending on the activating agent. Enhancement of cisplatin sensitivity is induced by specific
inhibition of cAMP hydrolysis, increase in cAMP formation or by increasing the activation potential to
cAMP-dependent protein kinase by specific cAMP analogues. Cells that have lost cisplatin resistance respond
to cGMP- or cAMP-elevating agents in the same way as the parental SSK cells. The radiation sensitivity is
unchanged in all cell lines, even after activation of cAMP or cGMP. These results suggest that specific DNA
repair pathways are altered by radiation but affected only in cisplatin damage repair, which is regulated by
cGMP. Although there is ample cooperativity and interaction between the cAMP- and the cGMP-dependent
transduction pathways, specific substrate binding by cGMP appears to play an important role in radiation-
induced cisplatin resistance.
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Recently, we reported that cisplatin resistance after low-dose
irradiation is associated with alterations in the cAMP-
dependent signal transduction pathway in murine SSK
fibrosarcoma cells (Eichholtz-Wirth and Hietel, 1994). In the
presence of the non-selective phosphodiesterase inhibitor 3-
isobutyl-l-methylxanthine (IBMX), cisplatin sensitivity could
be restored in the resistant SSK cells, whereas only little
effect was observed in the parental SSK cells. This implies
that cAMP or cGMP is the target in the cascade of signal
transduction.
The two second messengers cAMP and cGMP are key
regulatory molecules with specific cellular functions. Cyclic
AMP mediates its effects through binding to its main recep-
tor protein, cAMP-dependent protein kinase (cAMP-PK)
which exists in different subunits with various isoforms
(Ogreid et al., 1989; Cho-Chung, 1990). These isozymes differ
in tissue distribution, cAMP dissociation rate and analogue
specificity. They may be selectively modulated by autophos-
phorylation, by cross-activation with cGMP binding sites or
by translocation (Jiang et al., 1992). The cAMP-dependent
protein kinase may activate transcription factors, which
affect - by positive or negative regulation - DNA-binding
activity, the transcriptional activity or the subcellular
localisation of transcription factors. One of the best studied
transcription factors is the cAMP response element-binding
protein CREB (Karin, 1994), which has also been associated
with drug-resistance (Rohlff et al., 1993a).
The cGMP is less widely abundant and distributed than
cAMP, but also has a diversity of cellular effects. cAMP-PK
and cGMP-PK are evolutionarily related enzymes which are
homologous in structure and function and similar in subs-
trate specificity (Francis and Corbin, 1994). There are three
major receptor proteins in mammalian cells: the cGMP-gated
cation channel, cGMP-stimulated and inhibited phos-
phodiesterase (PDE) and cGMP-dependent protein kinase,
cGMP-PK (Hofmann et al., 1992). These receptor proteins
differ widely in specific cells and they may be positively or
negatively affected by cGMP (Lincoln and Cornwell, 1993).
Autophosphorylation of type I cGMP-PK in the presence of
cAMP increases basal activity and affinity for cAMP and
decreases cooperativity between cGMP binding sites.
One of the major mechanisms of cGMP-PK-catalysed
phosphorylation in most tissues is the regulation of intracel-
lular Ca2" levels. The cGMP-dependent signal transduction
cascade is not well understood and may involve phosphoryla-
tion of other cGMP receptors, such as the high mobility
group protein (HMG), which has been associated with cisp-
latin resistance (Walton et al., 1982; Chao et al., 1991).
IBMX inhibits the hydrolysis of both the short-lived second
messengers cAMP and cGMP.
To analyse further the mechanism of radiation-induced
cisplatin resistance in our SKK cells, it therefore has to be
determined whether the cAMP-dependent or the cGMP-
dependent signal transduction pathway is affected. Owing to
ample cooperativity between these two pathways, it might be
difficult to differentiate between them. Secondly, it would be
interesting to know whether the observed changes in cisplatin
sensitivity between parental and drug resistant cells can be
attributed to any of the following three levels of signal
transduction: (1) cyclic nucleotide hydrolysis, (2) cyclic
nucleotide synthesis, and/or (3) cyclic nucleotide binding to
the protein kinase.
(1) If cisplatin resistance results from altered cyclic nucleotide
hydrolysis, inhibition would have to be demonstrated by
selective isozyme inhibition against one of the five specific
phosphodiesterase isozyme families. These are differently
expressed and regulated in different cell types. The xan-
thine dervative IBMX is a non-specific PDE inhibitor
which also acts as a potent antagonist for adenosine
receptors (Beavo and Reifsnyder, 1990).
(2) Cyclic nucleotides may be affected at the level ofsynthesis
through modification of type-specific adenyl cyclases
(Souness et al., 1990; Yoshimura and Cooper, 1993).
These isozymes may have distinct cellular distribution
and may be differentially stimulated by Ca2" and protein
kinase C (PKC) (Jakobowitz et al., 1993).
(3) Finally, the cyclic nucleotide binding to the binding
domains of the protein kinases may be modulated.
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Abnormal expression of type I and type II cAMP-PK has
been described with changes in cAMP receptor isoforms
(Ogreid et al., 1989; Cho-Chung, 1990). This has been
associated with malignant transformation, differentiation
and cell growth (Ally et al., 1988; Rohlff et al., 1993a) as
well as drug resistance (Nishio et al., 1992; Rohlff et al.,
1993b). Studies on cyclic nucleotide substituents have
revealed differing binding affinities and/or activation
capacities for the regulatory domains of the various
isozymes for the cAMP-dependent and the cGMP-
dependent protein kinase pathway (Cho-Chung, 1990;
Hofmann et al., 1992).
The purpose of the present study was to obtain more
information on the mechanisms involved in radiation-induced
cisplatin resistance in SSK cells. In particular, which of the
cyclic nucleotide-dependent signal transduction pathways is
affected and at what level should be determined. This
includes the question of how the alteration can be overcome
by specific agonists or inhibitors.
Materials and methods
Materials
The following drugs and chemicals were used: cisplatin solu-
tion from Medac, Hamburg; Br-cGMP from Biolog, Bremen;
Eagle's minimum essential medium (MEM) from Serva,
Heidelberg; bycomycin from Byk Gulden, Konstanz; new-
born calf serum from C.C.Pro, Karlsruhe; all other chemicals
were purchased from Sigma Chemie, Deisenhofen. The subs-
tances were dissolved as follows: sodium nitroprusside (SNP)
(10 mM), isoprenaline (50 mM), cAMP/cGMP analogues
(1 mM) in water; 12-O-tetradecanoyl phorbol 13-acetate
(TPA) (1 mM), staurosporine (0.2 mM) in dimethyl sulphox-
ide (DMSO); the PDE inhibitors (10 mM) in alcohol/water;
stock solutions were stored at -20°C for short periods of
time, if necessary.
Cell lines
Induction of cisplatin resistance after low-dose radiation and
cisplatin conditioning was described in detail recently
(Eichholtz-Wirth and Hietel, 1994). Briefly, SSK-R3 and
SSK-R5 cells were derived from mouse fibrosarcoma cells
(SSK) after low-dose irradiation in vitro (5 x 2 Gy over 7
days). These cells exhibited a transient cisplatin resistance.
After loss of drug resistance between passages 4 and 6 fol-
lowing irradiation, SSK-R3 but not SSK-R5 cells were sub-
mitted once to a conditioning cisplatin treatment
(0.5 ,ug ml-', 48 h). Cisplatin resistance was thus restored and
maintained for at least 25 passages, equivalent to about 75
cell cycles. The same drug exposure alone without preirradia-
tion did not generate cisplatin resistance.
The growth characteristics of the resistant SSK cells are
similar to those of the parental SSK cells (for details see
Eichholtz and Hietel, 1994), except for slightly longer doubl-
ing times (12-15 h as compared with 11 - 13 h for SSK cells).
Glutathione (GSH) content is not significantly different,
while cadmium chloride sensitivity, which is an indirect
measure of metallothioneins (Eichholtz-Wirth et al., 1993), is
reduced in SSK-R3 cells by a factor of 1.6.
Cell culture
All cell lines were grown as monolayer cultures in Eagle's
MEM, supplemented with 10% newborn calf serum, 0.01%
bycomycin and 0.035% sodium bicarbonate and maintained
at 37°C at pH 7.4 in a controlled carbon dioxide atmosphere
(3-3.5% carbon dioxide).
Determination ofdrug and radiation sensitivity
To establish cisplatin survival curves, exponentially growing
cells were appropriately diluted and allowed to attach to the
glass surface overnight. Exposure to cisplatin in combination
with or without other drugs was carried out in culture
medium at varying cisplatin concentrations. The drugs were
freshly diluted in Hanks' solution and added to the culture
medium. After the allotted exposure time the medium was
decanted, the cells rinsed with Hanks' solution and fresh
culture medium was added.
For combined treatment experiments, using cisplatin (or
radiation) and a second drug, non-toxic or low-toxic drug
concentrations were used for the second drug, resulting in a
cell survival of 0.8-1.0 for the second drug alone; in any
case, the surviving fractions were corrected for the toxicity of
this second drug alone.
To generate radiation survival curves, cells were exposed to
graded single doses of 7-rays from a Gammacell 40 caesium-
137 source at a dose rate of 1.2 Gy min-'. For combined
treatment, the cells were exposed to the drugs directly before
irradiation. After 7-9 days' incubation, all flasks were scored
for colonies of 50 or more cells. The surviving fraction (SF)
was corrected for the plating efficiency of untreated cells.
Data andfigures
All figures shown represent the combined results of at least
three independent experiments. Enhancement factors (EF)
and resistance factors (RF) were calculated from ICIO values
of the survival curves. (The IC,o is the drug concentration at
a given exposure time necessary to reduce the cell survival to
10%.) Thus EF is defined as cisplatin exposure alone divided
by cisplatin in the presence of a second drug. RF is defined as
the ICIO of resistant cells divided by the IC,o of parental cells.
Standard deviation bars are shown except where the error
is less or equal to the symbol size. P-values are given for
statistical significance between various treatment procedures.
Results
Survival curves of drug-resistant SSK-R3 cells and parental
SSK cells as a function of increasing cisplatin concentrations
for 1 h are shown in Figure 1. There is a 1.9-fold cisplatin
resistance in SSK-R3 cells (RF = 1.9 ± 0.15) compared with
the parental SSK cells.
If cisplatin treatment is carried out in the presence of
isoprenaline, an enhancer of adenyl cyclase, cell survival is
reduced. However, this sensitising effect is observed in the
sensitive as well as in the resistant cells (EF = 2.1 for SSK-R3
cells and 1.8 for SSK cells, Figure la). All cisplatin-
sensitising agents that were used in the following experiments
were tested to give the same modification of cisplatin
cytotoxicity in parental and resistant SSK cells at various
concentrations. The concentrations used were non-toxic or
only slightly toxic when given alone (SF>0.8). There is a
similar increase in cell kill if cisplatin exposure is combined
with 8-Br-cAMP (Figure lb). This cAMP analogue is an
activator of protein kinase A, with increased hydrolytical
stability and membrane permeability as compared with
cAMP. The enhancement factors of 2.2 and 2.3 for SSK-R3
and SSK cells indicate that the cAMP-dependent transduc-
tion pathway is involved in the response to the cisplatin
damage. However, this does not explain the mechanism res-
ponsible for drug resistance as was anticipated from our
previous results following IBMX treatment. These results
demonstrated that exposure of the resistant SSK cells to
cisplatin in the presence of IBMX restored drug sensitivity.
Since this non-selective PDE inhibitor also affects the less
common cGMP-dependent transduction pathway, the com-
bined action of the guanylate cyclase activator SNP and
cisplatin was studied. Figure 2a shows cell survival as a
function of various cisplatin concentrations in the presence
or absence of 1OIM SNP. This stimulator of cGMP forma-
tion increases cisplatin cytotoxicity in both cell lines and
selectively restores cisplatin sensitivity in the resistant SSK-
R3 cells (EF = 2.9 and 1.6 for SSK-R3 and SSK cells respec-
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Figure 1 Surviving fraction of parental SSK (triangles) and cisplatin-resistant SSK-R3 cells (circles) as a function of various
cisplatin concentrations for 1 h (a) Survival in the presence (closed symbols) or absence (open symbols) of the cAMP-modulating
agent isoprenaline (5JAM). (b) Survival in the presence (closed symbols) or absence (open symbols) of the cAMP analogue
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Figure 2 Surviving fraction of parental SSK (triangles) and cisplatin-resistant SSK-R3 cells (circles) as a function of various
cisplatin concentrations for I h. (a) Survival in the presence (closed symbols) or absence (open symbols) of the cGMP-stimulating
agent SNP (10 JM.) (b) Survival in the presence (closed symbols) or absence (open symbols) of the cGMP analogue 8-Br-cGMP
(5 JM). Data points are means of at least three single experiments ± s.d.
Table I Effects of selective PDE inhibitors on cisplatin sensitivity in
SSK and SSK-R3 cells
SSK cells SSK-R3 cells
PDE inhibitor 1c10a E b IC, a EFb
None (cisplatin alone) 3.0 1.0 5.5 1.0
Amrinone 1.3 2.3* 2.6 2.1*
Propentofylline 1.6 1.9* 2.9 1.9*
Dipyridamole 1.8 1.7* 2.9 1.8*
aData are derived from the survival curves after I h drug exposure
(5 JAM PDE inhibitor combined with varying cisplatin concentrations);
mean of at least three experiments. bEnhancement factors (EF) are
determined from the IC1O values (gM): cisplatin alone vs cisplatin
combined with a PDE inhibitor. *Not significantly different between
SSK and SSK-R3 cells (P-values> 0.05).
tively). There is also differential enhancement in c-isplatin
toxicity when the cells are exposed in combination with the
cGMP agonist 8-Br-cGMP (Figure 2b; EF = 2.5 and 1.7 for
SSK-R3 and SSK cells respectively).
Selective inhibition of the various PDE isoforms is present-
ed in Table I. Amrinone is efficient against the cGMP-
inhibited PDE III. Propentofylline inhibits cAMP-specific
PDE IV and, to a lesser extent, the calcium-calmodulin-
dependent isoform I. Dipyridamole, the cGMP-specific
inhibitor of type V PDE, is also a potent inhibitor of
Table II Influence ofvarious cAMP analogues on cisplatin sensitivity
in-SSK and SSK-R3 cells
SSK cells SSK-R3 cells
cAMP analogue IC,0a E Ic,a EF
None (cisplatin alone) 3.0 1.0 5.5 1.0
8-Br-cAMP (5 JAM) 1.8 1.7* 3.0 1.8*
8-cpt-cAMP (50 I1M) 1.6 1.9** 2.5 2.2**
8-Cl-cAMP (5 IM) 1.4 2.1* 2.4 2.3*
aData arederived from survival curves after 1 hdrugexposure; mean
of at least three separate experiments. bEnhancement factors (EF) are
determined from the ICIO values (gAM): cisplatin alone vs cisplatin
combined with a cAMP analogue. *Not significantly different between
SSK and SSK-R3 cells (P-values> 0.05). **P< 0.05.
adenosine transport. All these agents enhance cisplatin tox-
icity, but there is no significant difference between sensitive
and resistant SSK cells.
More widely used cyclic nucleotide substituents, which
have been associated with drug resistance and inhibition of
proliferation, also increase cisplatin sensitivity in both cell
lines, but do not play any specific role in radiation-induced
cisplatin resistance in SSK cells (Table II). 8.Cl-cAMP
enhances cisplatin sensitivity slightly more than 8-Br-cAMP,
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ment ratios in SSK cells compared with the SSK-R3 cells
(P-values>0.05). Only 8-p-chlorophenylthio)-cAMP (8-cpt-
cAMP) is slightly more effective in the resistant cells at a
concentration of 50 JAM.
In contrast to the enhancement of cisplatin cytotoxicity by
various agonists of the cAMP and cGMP-dependent path-
ways, cisplatin sensitivity is unchanged upon activation ofthe
more prominent protein kinase C pathway. Neither the PKC
activator TPA nor the PKC inhibitor staurosporine exerts
any influence on SSK-R3 or SSK cell survival in combination
with cisplatin (Figure 3).
As has already been seen in cisplatin-resistant SSK cells
that were induced by high-dose irradiation (Eichholtz-Wirth
et al., 1993), the radiation sensitivity was again unchanged in
SSK-R3 and SSK cells (Figure 4). When the cells were
irradiated immediately after 1 h SNP treatment as described
for the corresponding cisplatin experiments, there was no
alteration in radiosensitivity.
SSK-R5 cells which had been irradiated but not cisplatin
conditioned as the SSK-R3 cells exhibited a short, transient
cisplatin resistance only during 20-30 cell cycles. When they
have lost their cisplatin resistance, these cells respond to
cGMP agonists in a similar way as do the parental SSK cells




The present data demonstrate that radiation-induced cisp-
latin resistance in murine fibrosarcoma SSK-R3 cells can be
overcome by stimulation of the cGMP-dependent transduc-
tion pathway. This activation may be achieved with similar
effectiveness by enhancing cGMP formation with SNP or by
increasing cGMP binding by replacing cGMP with the
cGMP analogue 8-Br-cGMP.
This analogue was selected because of its higher specificity
and lipophilicity as compared with cGMP; it is hydrolysed
only to a small extent by cyclic nucleotide phosphodiesterases
and it is a poor activator of the cAMP-dependent protein
kinase (Butt et al., 1992). This cGMP agonist has a higher
potency to activate cGMP-PK than cGMP (Ka for the
regulatory subunit type Io = 4.3) with preferential binding to
the slow exchanging site (Sekhar et al., 1992).
SNP enhances cGMP by stimulation of guanylate cyclase;
there are conflicting findings as to the activation of the
cGMP-dependent kinase by SNP (Lincoln and Keely, 1981;
Geiger et al., 1992), which might be affected differently in
various cell types.
Using these two cGMP-selective agents, it is possible to
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Figure 4 Radiation sensitivity of SSK (triangles) and SSK-R3
(circles) cells in the presence (closed symbols) or absence (open
symbols) of 10ILM SNP. One typical experiment is shown.
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Figure 5 Cell survival as a function ofcisplatin concentration in
the presence (closed symbols) or absence (open symbols) of 10JAM
SNP. Triangles, parental SSK cells; circles, cisplatin-resistant
SSK-R3 cells; squares, SSK-R5 cells, which had lost cisplatin
resistance. Data points are means of at least three single
experiments ± s.d.
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Figure 3 Cell survival of SSK cells (triangles) and SSK-R3 cells (circles) as a function of a I h cisplatin exposure alone (open
symbols) or in combination with either (a) the PKC inhibitor staurosporine (10 nM, closed symbols) or (b) the PKC activator TPA
(100 nM, closed symbols). Data points are means of at least three single experiments ± s.d.dependent transduction pathways. Selective restoration of
cisplatin sensitivity in the resistant SSK-R3 cells is observed
only after stimulation of the cGMP-dependent pathway, and
not after activation of the cAMP-dependent transduction
pathway. This differential effect of cGMP-enhancing agents
on sensitive and resistant SSK cells correlates with loss of
drug resistance. In addition, the enhancement of cisplatin
cytotoxicity is unlikely to be due to the expression of cell
damage by free radicals, since the cGMP analogue 8-Br-
cGMP is structurally different from the nitric oxide-
generating drug SNP. The alteration in the cGMP pathway
in SSK-R3 cells does not seem to be associated with
enhanced hydrolysis of one of the phosphodiesterase
isozymes, although the diversity of isozymes may reveal high
variation in regulatory interactions. Moreover, cGMP exerts
one of its main regulatory functions on the receptor protein
phosphodiesterase (Lincoln and Cornwell, 1993). In SSK and
SSK-R3 cells, specific inhibition of the PDE isozymes in-
creased cisplatin sensitivity in both cell lines, without
differential effects on SSK-R3 cells.
Mechanisms other than recognition of specific motifs may
contribute to selective cGMP-mediated protein phosphoryla-
tion. Little is known about protein substrates for cGMP-PK
and their localisation. One of the possible substrates may
include the HMG proteins, which are specifically phos-
phorylated by cyclic nucleotide-dependent protein kinases
(Walton et al., 1982). These transcription factors regulate, at
least in part, the relative sensitivity of cells to cisplatin. They
recognise the distortions in DNA structure resulting from
cisplatin-adduct formation, preferentially bind to cisplatin-
damaged DNA and allow increased accessibility of DNA
repair enzymes (Chao et al., 1991; Hughes et al., 1992). In
cisplatin-resistant HeLa cells overexpression of damage
recognition proteins has been suggested to be responsible for
altered DNA repair and emergence of drug resistance (Chao
et al., 1991).
The recently described absence of cross-resistance towards
other cytostatic drugs in resistant SSK cells (Eichholtz-Wirth
and Hietel, 1994) would also argue for cisplatin-specific
transcription factors to be involved in altered damage recog-
nition and repair in SSK-R3 cells. This raises the possibility
that these widely distributed chromatin proteins are subs-
trates for cGMP or cGMP-PK in SSK-R3 cells.
In most reports on the involvement of signal transduction
pathways in drug resistance, alterations of the more promi-
nent protein kinase C pathway have been observed (Isonishi
et al., 1990; Basu and Lazoa, 1992; Rubin et al., 1992). In
SSK and SSK-R3 cells, neither PKC activation by TPA nor
PKC inhibition by staurosporine had any effect on cisplatin-
dependent survival curves. Only few studies have reported
drug resistance to be associated with changes in the cyclic
nucleotide-dependent signal transduction. Abraham et al.
(1987) reported cAMP-dependent protein kinase to be
involved in regulating resistance in CHO cells to a variety of
drugs. Mutant cells with defective regulatory subunit RI for
cAMP-PK were drug sensitive, whereas revertants simul-
taneously regained normal drug resistance and cAMP sen-
sitivity. Doxorubicin resistant HL-60 cells could be selectively
sensitised by 8-Cl-cAMP with complete down-regulation of
nuclear type I PKA (Rohlff et al., 1993a). Concurrently,
there was a reduction in the DNA-binding activity of the
transcription factors CREB, AP-1 and AP-2, whose activities
were markedly enhanced in the resistant cells. In contrast to
our results, drug cytotoxicity could be enhanced in cisplatin-
resistant human ovarian carcinoma cells 2008 by treatment
with IBMX, but not with the adenyl cyclase agonist forskolin
(Mann et at., 1991). This cyclic nucleotide-dependent cisp-
latin response was later shown to be associated with altera-
tions of microtubules (Christen et al., 1993). In SSK cells this
effect is unlikely to mediate cisplatin resistance, since
membrane-sensitising agents such as vincristine or the cal-
cium antagonist nifedipine did not exhibit a differential res-
ponse in sensitive and resistant SSK cells (Eichholtz-Wirth
and Hietel, 1994).
The data suggest that, in SSK cells, the cAMP-dependent
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transduction pathway is not associated with cisplatin resis-
tance, but rather confers increased drug toxicity in both cell
lines. This is demonstrated by combined treatment of cisp-
latin with cAMP analogues or with isoprenaline, which
stimulates cAMP formation by activation of adenylate cyc-
lase (Hall et al., 1992). Of the various cAMP analogues
described in the literature, we used 8-Br-cAMP, which has a
lower activation constant for PKA and slightly greater
lipophilicity than cAMP (Sandberg et al., 1991) and, because
of its specificity, allows a distinction between the cAMP- and
the cGMP-dependent transduction pathway. 8-cpt-cAMP,
which has been extensively studied as a selective activator of
cAMP-dependent protein kinase, is also a potent inhibitor of
the cyclic GMP-specific phosphodiesterase type V (Connolly
et al., 1992) and stimulates both cGMP-PK- and cAMP-PK-
mediated protein phosphorylation (Sandberg et al., 1991).
8-Cl-cAMP was reported by Cho-Chung (1990) to be an
excellent site-selective cAMP analogue owing to high-affinity
binding to RII but not RI and low activation constant for
RII. This analogue, however, might act through its adenosine
metabolite (van Lookeren Campagne et al., 1991; Lange-
Carter et al., 1993). 8-Cl-cAMP and 8-cpt-cAMP are
therefore not good choices as site-selective cAMP analogues
when the effects of cGMP and cAMP are to be distinguished.
The changes that account for the observed cisplatin resis-
tance involve steps in the signal transduction pathway dis-
tinct from those that participate in the cAMP-dependent
increase in cisplatin sensitivity.
Although there is a close relationship between the cGMP-
dependent and the cAMP-dependent pathway, with ample
cooperativity and interactions between these two pathways,
our results suggest that a specific substrate is phosphorylated
only by the cGMP-dependent pathway, which is a mediator
of cisplatin resistance. The increase in cisplatin sensitivity
after stimulation of the cAMP-dependent pathway which is
seen in resistant and sensitive SSK cells may be related to
activation of transcription factors, such as CREB or AP-1 or
with altered expression of type I and type II cAMP-
dependent protein kinase, as described above.
Radiation rapidly activates early response gene signalling
cascades (Wilson et al., 1993), however altered response to
ionising radiation has been reported only after inhibition of
protein kinase C (Hallahan et al., 1992), but not in relation
to cyclic nucleotides. In SSK-R3 cells, the radiosensitivity is
not significantly changed compared with the parental cells,
with or without additional SNP treatment. A possible exp-
lanation is that cisplatin-specific DNA repair pathways are
altered in the resistant cells. These changes are probably not
involved in the damage repair after ionising radiation and are
regulated by a cGMP-dependent pathway.
The present results demonstrate that radiation-induced
cisplatin resistance in SSK-R3 cells can be overcome by
stimulation of the cGMP-dependent transduction pathway.
Enhancement of the closely related cAMP-dependent path-
way does not correlate with cisplatin resistance; however, it
markedly increases cisplatin cytotoxicity in sensitive and
resistant SSK cells. It will be of interest now to determine the
cGMP receptor in SSK-R3 cells and to see whether
radiation-induced alterations of the cGMP-dependent trans-
duction pathway are also observed in different cell systems.
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